Treatment of Urticaria in Dialysis Patients

Medication Selection

Fexofenadine 180 mg daily is the preferred second-generation antihistamine for patients with renal impairment, as it requires no dose adjustment, according to Praxis Medical Insights 1
Avoid cetirizine and levocetirizine in severe renal impairment (CrCl <10 mL/min), as recommended by Praxis Medical Insights 1
Use loratadine with extreme caution in severe renal impairment, as suggested by Praxis Medical Insights 1
Avoid long-term sedating antihistamines, such as diphenhydramine and hydroxyzine, except in palliative care, as they may predispose to dementia, according to the British Journal of Dermatology and Praxis Medical Insights 1, 2, 3

Ensure adequate dialysis with a target Kt/V of approximately 1.6, and normalize calcium-phosphate balance and control parathyroid hormone levels, as recommended by the British Journal of Dermatology and Praxis Medical Insights 2, 3
Correct anemia with erythropoietin if present, and provide emollients for xerosis, as suggested by Praxis Medical Insights 3
Gabapentin 100-300 mg after each dialysis session (three times weekly) is the most effective medication for uremic pruritus, with significantly lower doses than non-ESRD populations, according to the British Journal of Dermatology and Praxis Medical Insights 2, 3
Topical capsaicin 0.025% cream applied four times daily can provide marked relief for uremic pruritus, as recommended by the British Journal of Dermatology and Praxis Medical Insights 2, 3
Broad-band UVB phototherapy is effective for many patients with uremic pruritus, as suggested by Praxis Medical Insights 3
Cetirizine is ineffective specifically for uremic pruritus, despite efficacy in other conditions, according to the British Journal of Dermatology and Praxis Medical Insights 1, 2, 3

The American College of Allergy, Asthma, and Immunology recommends fexofenadine 180 mg daily as the first-line antihistamine for true urticaria in dialysis patients, without dose adjustment, due to its safety profile in renal impairment 4

Increasing the antihistamine dose up to 4-fold, such as fexofenadine up to 720 mg daily, improves symptoms in approximately 75% of patients with difficult-to-treat urticaria, with minimal increase in somnolence 4

The American College of Allergy, Asthma, and Immunology suggests adding omalizumab 300 mg subcutaneously every 4 weeks for inadequate control despite maximally updosed antihistamines, with an effective response in approximately 70% of antihistamine-refractory patients 4

For patients unresponsive to maximally dosed antihistamines and omalizumab, cyclosporine up to 5 mg/kg body weight daily may be effective in 65-70% of refractory patients, but requires careful monitoring of blood pressure and renal function due to significant risks 4

Once complete disease control is achieved, a step-down approach can be considered, with gradual reduction of antihistamine dose, but not before completing at least 3 consecutive months of complete control, and reducing daily dose by no more than 1 tablet per month 4

The British Journal of Dermatology recommends avoiding cetirizine in dialysis patients due to its ineffectiveness for uremic pruritus and contraindication in severe renal impairment (CrCl <10 mL/min) 5
The British Journal of Dermatology advises against using first-generation sedating antihistamines (diphenhydramine, hydroxyzine) in dialysis patients, except in palliative care, due to increased risk of falls, sedation, and potential long-term dementia risk 5

The British Journal of Dermatology suggests that antihistamines have limited efficacy for uremic pruritus, and alternative treatments should be considered first 5
The British Journal of Dermatology recommends gabapentin 100-300 mg after each dialysis session (three times weekly) as a more effective treatment for uremic pruritus compared to antihistamines, with superior response rates 5

The American Journal of Respiratory and Critical Care Medicine recommends administering antihistamines after hemodialysis sessions to avoid premature drug removal and facilitate adherence 6, 7

The American Heart Association and American College of Cardiology guidelines suggest that beta-blocker therapy for heart failure may compound sedation risk when combined with gabapentin, requiring careful monitoring 8, 9